MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

MAXCYTE, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.30+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $138.87M
P/E (TTM): –
Dividend yield: –

Dividends

Maxcyte has not reported a dividend

No dividend per share appears in Maxcyte's annual filings since fiscal 2018.

Where these numbers come from

Parsed from the XBRL in Maxcyte's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MXCT.

Revenue growth-13.2% · median 44.0%

Operating margin-134.6% · median -125.8%

Net margin-114.8% · median -186.2%

Company	Revenue	Growth
NRC	$140.00M	-0.2%
OABI	$38.46M	+67.0%
MXCT	$31.05M	-13.2%
FOXO	$17.86M	+44.0%
BIAF	$5.90M	-23.2%
ONMD	$1.46M	+216.5%

Company

Next earnings (est.): Nov 4, 2026, after close
Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 91
Held by institutions: 61.3%
Auditor: CohnReznick LLP
SEC CIK: 1287098

Advertisement
300 × 250